
Exelixis CEO Michael Morrissey reported strong commercial growth for cabozantinib, with revenue projected to surpass $2.1 billion this year, driven by demand in RCC and a successful initial launch in neuroendocrine tumors (NETs), supporting an aspirational $3 billion peak by 2030. The company also announced positive top-line results for zanzalintinib's STELLAR-303 trial in late-line colorectal cancer, with regulatory filing discussions ongoing, positioning zanza as a future $5 billion peak asset and a key element in the planned transition from cabozantinib. Exelixis continues to advance a deep oncology pipeline, including XB371 and XL309, while maintaining approximately $1 billion in annual R&D spend and executing share repurchases to build long-term shareholder value and mitigate future patent cliffs.
Exelixis is demonstrating strong commercial execution with its primary value driver, cabozantinib, which is on track to exceed $2.1 billion in revenue this year, up from $1.8 billion last year. This growth is primarily demand-driven, highlighted by a 19% year-over-year revenue increase in Q2, an 18% rise in demand, and a steady gain of approximately one percentage point of market share per quarter in frontline Renal Cell Carcinoma (RCC). The recent launch in neuroendocrine tumors (NET) has had a robust start, capturing a 35% market share and contributing roughly $20 million in its first full quarter, reinforcing the company's aspirational $3 billion peak sales target for the cabozantinib franchise. Concurrently, the company is actively de-risking its future pipeline with zanzalintinib, which achieved positive top-line results in the STELLAR-303 trial for late-line colorectal cancer (CRC). This win in the broad intent-to-treat (ITT) population is particularly significant given recent failures by competitors in this setting and positions zanzalintinib as a potential $5 billion peak sales asset. The overarching strategy is to orchestrate a smooth transition from cabozantinib to zanzalintinib before the former's patent expiration around 2030, aiming to mitigate the patent cliff. This is supported by a disciplined capital allocation strategy, including a ~$1 billion annual R&D budget and a significant share repurchase program that has returned $1.8 billion to shareholders over the past two years.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment